Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects a new drug, palbociclib, has on
prostate cancer and will look at the side effects of treatment with palbociclib. The
researchers doing this study are also interested in looking for markers that may help predict
which patients are most likely to be helped by palbociclib and to see how the cancer cells
respond to palbociclib.